274 related articles for article (PubMed ID: 26081252)
1. Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary.
Takeuchi H; Saeki T; Aiba K; Tamura K; Aogi K; Eguchi K; Okita K; Kagami Y; Tanaka R; Nakagawa K; Fujii H; Boku N; Wada M; Akechi T; Udagawa Y; Okawa Y; Onozawa Y; Sasaki H; Shima Y; Shimoyama N; Takeda M; Nishidate T; Yamamoto A; Ikeda T; Hirata K
Int J Clin Oncol; 2016 Feb; 21(1):1-12. PubMed ID: 26081252
[TBL] [Abstract][Full Text] [Related]
2. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis.
Aogi K; Takeuchi H; Saeki T; Aiba K; Tamura K; Iino K; Imamura CK; Okita K; Kagami Y; Tanaka R; Nakagawa K; Fujii H; Boku N; Wada M; Akechi T; Iihara H; Ohtani S; Okuyama A; Ozawa K; Kim YI; Sasaki H; Shima Y; Takeda M; Nagasaki E; Nishidate T; Higashi T; Hirata K
Int J Clin Oncol; 2021 Jan; 26(1):1-17. PubMed ID: 33161452
[TBL] [Abstract][Full Text] [Related]
3. Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.
Aapro M; Scotté F; Escobar Y; Celio L; Berman R; Franceschetti A; Bell D; Jordan K
Oncologist; 2021 Jun; 26(6):e1073-e1082. PubMed ID: 33555084
[TBL] [Abstract][Full Text] [Related]
4. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
[TBL] [Abstract][Full Text] [Related]
5. Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential.
Olver I; Clark-Snow RA; Ballatori E; Espersen BT; Bria E; Jordan K
Support Care Cancer; 2011 Mar; 19 Suppl 1():S33-6. PubMed ID: 20803222
[TBL] [Abstract][Full Text] [Related]
6. Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
Basch E; Prestrud AA; Hesketh PJ; Kris MG; Feyer PC; Somerfield MR; Chesney M; Clark-Snow RA; Flaherty AM; Freundlich B; Morrow G; Rao KV; Schwartz RN; Lyman GH;
J Clin Oncol; 2011 Nov; 29(31):4189-98. PubMed ID: 21947834
[TBL] [Abstract][Full Text] [Related]
7. Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy--a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines.
Yu S; Burke TA; Chan A; Kim HK; Hsieh RK; Hu X; Liang JT; Baños A; Spiteri C; Keefe DM
Support Care Cancer; 2015 Jan; 23(1):273-82. PubMed ID: 25115892
[TBL] [Abstract][Full Text] [Related]
8. Changes in compliance with Japanese antiemetic guideline for chemotherapy-induced nausea and vomiting: a nationwide survey using a distributed research network.
Hori K; Kobayashi N; Atsumi H; Nagayama A; Kondoh M; Noge I; Kimura M; Utsugi H; Iwasaki T; Nakamura M; Kimura T
Support Care Cancer; 2014 Apr; 22(4):969-77. PubMed ID: 24276954
[TBL] [Abstract][Full Text] [Related]
9. State of the Art Antiemetic Therapy for Cancer Patients.
Lau TK; Yip CH; Yeo W
Curr Oncol Rep; 2016 Jan; 18(1):2. PubMed ID: 26694923
[TBL] [Abstract][Full Text] [Related]
10. Clinical practice guidelines on antiemetics in oncology.
Aranda Aguilar E; Constenla Figueiras M; Cortes-Funes H; Diaz-Rubio García E; Gascon Vilaplana P; Guillém V; Martin-Algarra S
Expert Rev Anticancer Ther; 2005 Dec; 5(6):963-72. PubMed ID: 16336087
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
Trigg ME; Higa GM
J Oncol Pharm Pract; 2010 Dec; 16(4):233-44. PubMed ID: 20085961
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Single-dose First-generation 5-HT
Kaito D; Iihara H; Funaguchi N; Endo J; Ito F; Yanase K; Toyoshi S; Sasaki Y; Hirose C; Arai N; Kitahora M; Ohno Y; Itoh Y; Minatoguchi S
Anticancer Res; 2017 Apr; 37(4):1965-1970. PubMed ID: 28373467
[TBL] [Abstract][Full Text] [Related]
14. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.
Hesketh PJ; Kris MG; Basch E; Bohlke K; Barbour SY; Clark-Snow RA; Danso MA; Dennis K; Dupuis LL; Dusetzina SB; Eng C; Feyer PC; Jordan K; Noonan K; Sparacio D; Somerfield MR; Lyman GH
J Clin Oncol; 2017 Oct; 35(28):3240-3261. PubMed ID: 28759346
[TBL] [Abstract][Full Text] [Related]
15. Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain.
Escobar Álvarez Y; De Castro Carpeño J; Bell D; Drago A; Franceschetti A
Clin Transl Oncol; 2021 Oct; 23(10):2155-2162. PubMed ID: 33956310
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study.
De Tursi M; Carella C; Tomao S; Cinieri S; Lorusso V; Marchetti P; Vecchio S; Sansoni E; Contu A; Adamo V; Silvestris N; Nuzzo A; Rosti G; Ravaioli A; Danova M; Tonini G; Passalacqua R; Cruciani G; Faedi M; Spada M; De Laurentiis M; Amoroso D; Tomao F; Sperduti I; Grassadonia A; Tinari N; Natoli C; Iacobelli S;
Tumori; 2014; 100(6):e309-13. PubMed ID: 25688518
[TBL] [Abstract][Full Text] [Related]
17. A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan.
Iihara H; Shimokawa M; Hayashi T; Kawazoe H; Saeki T; Aiba K; Tamura K
Oncologist; 2020 Feb; 25(2):e373-e380. PubMed ID: 32043774
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
19. 2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
Olver I; Ruhlmann CH; Jahn F; Schwartzberg L; Rapoport B; Rittenberg CN; Clark-Snow R
Support Care Cancer; 2017 Jan; 25(1):297-301. PubMed ID: 27572335
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Adherence to Antiemetic Treatment Guidelines in Patients With Chemotherapy-Induced Nausea and Vomiting in Teaching Hospitals in Tehran.
Nikbakht Z; Rajabi M; Shahrasbi A; Roohi E; Hashemian F
J Cancer Educ; 2021 Oct; 36(5):1022-1029. PubMed ID: 31955393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
